What happened
Biomatter announced on November 12, 2026 that it closed an oversubscribed $18 million Series A led by Astanor, with participation from existing investors UVC Partners, Inventure and Metaplanet, Unite.AI reports. The company will use the funding to expand its AI-powered enzyme-design work and commercial operations, including a 2,000-square-meter design-and-testing facility in Vilnius planned to open in 2027.
Unite.AI reports that Biomatter, a company using AI to design enzymes, announced on November 12, 2026 that it had closed an oversubscribed $18 million Series A led by Astanor, with participation from existing investors UVC Partners, Inventure and Metaplanet. The financing is intended to expand the company's AI-powered enzyme-design work and its commercial operations.
A central element of the expansion is a 2,000-square-meter design-and-testing facility in Vilnius that Biomatter plans to open in 2027, bringing more laboratory building and testing in-house. According to the report, the round will also grow the commercial team and US presence while funding further development of the computational platform and its underlying enzyme .
Biomatter says conventional enzyme development takes months or years, compared with weeks for its current programs, and that the added laboratory capacity is intended to shorten that cycle to days. The company's process starts with the chemistry a customer's product needs rather than with a natural enzyme, and it says years of generating enzyme data far from natural examples enable its models to make large jumps in sequence and structure. Each design is tested in the laboratory before shipment.
The report cites two product examples. In a collaboration with Thermo Fisher Scientific on Invitrogen SuperScript V Reverse Transcriptase, an enzyme used to convert RNA into DNA, Biomatter reports improved oxidation resistance contributing to reagent stability that supports ambient shipping and room- storage for up to six months. In another program, Biomatter created a methylase enzyme for mRNA vaccine manufacturing that works without SAM, an additive the company describes as expensive and required by every natural methylase.
Biomatter reports delivering more than 50 custom enzymes to over 25 enterprise customers across Europe, the United States and Japan, with named customers including AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos. Several accounts have reportedly progressed from single projects to multi-year, multi-enzyme programs, and roughly half of the company's customers are based in the United States. Astanor partner Harry Briggs said the investment case rested on Biomatter's data generation beyond natural examples and its repeat customer projects across industries.
Why it matters
The round funds a concrete attempt to compress enzyme development from months or years to days by pairing AI computational design with in-house laboratory testing. Biomatter reports more than 50 custom enzymes delivered to over 25 enterprise customers, including AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi and Tereos, which suggests commercial traction beyond the announcement itself.
The funding supports a concrete attempt to compress enzyme development timelines. Biomatter claims its current programs take weeks versus months or years for conventional development, and the new in-house laboratory capacity is intended to shorten cycles to days. These timeline claims are the company's own and are not independently verified.
The reported customer base gives the round practical beyond the financing itself: more than 50 custom enzymes delivered to over 25 enterprise customers across biopharmaceuticals, diagnostics, agriculture and industrial biotechnology, with several accounts reportedly becoming multi-year, multi-enzyme programs.
The model-data loop is the structural bet. Each program adds experimentally characterized enzymes to Biomatter's proprietary , which the company says makes subsequent programs faster and more accurate, tying commercial expansion and computational improvement together.
The Thermo Fisher and methylase examples illustrate practical impact: improved reagent stability enabling ambient shipping and room- storage for up to six months, and a methylase for mRNA vaccine manufacturing that works without SAM, an additive the company describes as expensive and required by every natural methylase.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
A route planner searches possible journeys using explicit rules. What does this illustrate about AI?
What to watch next
Whether the planned Vilnius facility opens on schedule in 2027 and actually shortens design-and-test cycles to days, whether Biomatter's US expansion deepens its customer base beyond the roughly half already based there, and whether the proprietary enzyme keeps improving model accuracy as more experimentally characterized enzymes are added.
Whether the Vilnius facility opens as planned in 2027 and whether in-house testing actually shortens development cycles to days while maintaining the laboratory validation behind customer programs.
How the expanded commercial team and US presence translate into new enterprise accounts, given that roughly half of current customers are already US-based.
Whether the proprietary enzyme continues to improve model speed and accuracy as more experimentally characterized enzymes are added, and whether customers convert from single projects into longer multi-enzyme programs.